Biotechnology News

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel – – Symvess...

MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology

Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens...

General Oncology nominated for 2026 Prix Galien USA Award for Best Startup, after preliminary Phase 1 results for GO-4 in BRCA-mutated pancreatic cancer.

Asimov will use its CHO Edge System to develop a high-titer cell line for Kaigene’s therapeutic candidate that selectively degrades pathogenic antibodies.

Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS...

PRESS RELEASE CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor LONDON – 18 August 2026 -- CHARM Therapeutics...

Company announcement no. 31 - 2618 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Total revenue increases by 14% to CHF 119 millionOperating profit increases by 32% to CHF 32 million and net profit by 77% to CHF 28 millionFosmanogepix phase 3 program on track for data readout and...

14 % Wachstum des Gesamtumsatzes auf CHF 119 Mio.32 % Steigerung des Betriebsgewinns auf CHF 32 Mio. und 77 % Steigerung des Gewinns auf CHF 28 Mio.Phase-3-Programm mit Fosmanogepix auf Kurs für die...